While some studies show evidence that βigH3 is tumor suppressive in early tumor development, several studies have seen βigH3 expression correlating to poor patient outcome with increased metastatic potential, decreased treatment response and decreased overall survival [32–36]. The gene discussed is TGFBI; the disease is neoplasm.